What makes hexarelin different from GHRP-6?

Hexarelin contains a D-2-methyl-tryptophan substitution that increases proteolytic resistance and GH-releasing potency compared with GHRP-6. Both peptides elevate cortisol and prolactin alongside GH, but hexarelin's co-stimulation is greater at equivalent doses. GHRP-6 also produces stronger appetite stimulation through ghrelin-related pathways that hexarelin does not replicate.

Does hexarelin affect the heart independently of GH?

Yes. Hexarelin binds CD36, a cardiac receptor structurally distinct from GHS-R1a. In rodent ischemia models, CD36-mediated effects include reduced infarct size, preserved cardiac output, and limited cardiomyocyte apoptosis. These effects persist in GH-deficient animal models, confirming the cardiac mechanism does not require pituitary GH secretion.

How quickly does the GH response decline with repeated hexarelin use?

In a 16-week twice-daily subcutaneous dosing study, mean GH AUC fell by approximately 45% from baseline by week 16. The decline was reversible: GH responses returned to near-baseline four weeks after stopping. Higher doses produce faster attenuation, so short-course protocols maintain a more consistent GH response than continuous administration.

How does hexarelin compare to ipamorelin for research use?

Hexarelin produces a stronger acute GH pulse but also raises cortisol, ACTH, and prolactin at equivalent GH-releasing doses. Ipamorelin is more GH-selective and is preferred when cortisol confounding is a concern. Hexarelin is the only common GHRP with confirmed CD36 cardiac binding, making it the tool of choice for cardiac growth hormone secretagogue research.

Was hexarelin approved for any medical use?

No. Hexarelin entered human clinical trials in the 1990s but was not approved in any major market. Its development program was discontinued. Tesamorelin, a structurally different GHRH analogue, later received FDA approval for HIV-associated lipodystrophy, but hexarelin's regulatory pathway was not pursued to approval.

What receptor mediates hexarelin's cardiac effects?

The primary receptor for hexarelin's GH-independent cardiac effects is CD36, a scavenger receptor expressed in cardiac muscle. Studies in CD36-null mice confirmed that cardioprotective effects in ischemia models were absent without this receptor. GHS-R1a is also present in cardiac tissue and contributes to some effects, but CD36 is the predominant mediator in peripheral cardiac regions.

Hexarelin research: GH release, cardiac effects, comparison

Hexarelin research covers two distinct pharmacological areas: potent growth hormone secretion through the GHS-R1a ghrelin receptor, studied in controlled human trials since the early 1990s, and cardioprotective effects in animal models through a structurally separate cardiac receptor that operates independently of pituitary GH release.

What is hexarelin

Hexarelin (INN: examorelin; developmental code EP-23905) is a synthetic hexapeptide with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. Mediolanum Farmaceutici developed it in the late 1980s as a more potent analogue of GHRP-6. The D-amino acid modifications confer resistance to proteolytic degradation compared with unmodified peptides of similar length.

Hexarelin belongs to the growth hormone secretagogue (GHS) class, synthetic compounds that bind the ghrelin receptor (GHS-R1a) and stimulate pituitary GH release. It was among the first GHRPs studied in controlled human clinical settings, with pharmacokinetic and dose-response trials conducted across several European research centers through the 1990s.

It is listed on DrugBank (DB13940) as a potent GH secretagogue with no approved therapeutic indication. The compound is also referenced in the CAS registry under its examorelin INN.

Mechanism of action

At the pituitary, hexarelin activates GHS-R1a through Gq/11-protein signaling, triggering GH release from somatotroph cells. At the hypothalamic level, it also stimulates endogenous GHRH secretion, which amplifies the pituitary GH signal. This dual central mechanism is one reason hexarelin produces greater GH release than equimolar GHRH or GHRP-6 alone.

Beyond the GH axis, hexarelin binds CD36, a scavenger receptor expressed in cardiac muscle, macrophages, and platelets. This receptor is structurally distinct from GHS-R1a and accounts for hexarelin's cardiac pharmacology. Cardioprotective effects persist in GH-deficient animal models, confirming that the CD36 pathway does not require pituitary GH secretion to operate.

For research comparing growth hormone secretagogues, the CJC-1295 and ipamorelin compound section covers how GHRH analogues are paired with GHRPs and how half-life differences affect protocol design.

GH secretion: what the human trials found

The main early pharmacokinetic study was published in the Journal of Clinical Endocrinology and Metabolism by Ghigo, Arvat, Deghenghi and colleagues (PMID 8126144, JCEM 1994). Twelve healthy young adult male volunteers received hexarelin by intravenous (1 and 2 mcg/kg), subcutaneous (1.5 and 3 mcg/kg), intranasal (20 mcg/kg), and oral (20 and 40 mg) routes in a crossover design. At 1 mcg/kg intravenously, hexarelin produced GH release approximately twice the level elicited by equimolar GHRH. A dose-response study established an ED50 of approximately 0.48 mcg/kg, with GH peak concentrations plateauing near 1.0 mcg/kg.

A follow-up comparison study published in the European Journal of Endocrinology (Arvat et al., PMID 9285939, 1997, n=10 healthy volunteers) placed hexarelin alongside GHRP-2 and found both peptides produced similarly strong GH responses, substantially greater than GHRH alone. Both also elevated cortisol, ACTH, and prolactin in a dose-dependent pattern, with hexarelin showing greater co-stimulation than GHRP-2 at comparable concentrations.

For researchers working with reconstituted hexarelin, the peptide dosing calculator handles mcg/ml concentration and unit volume conversions from U-100 syringe markings.

Cortisol and prolactin co-stimulation

Hexarelin activates corticotroph and lactotroph cell populations alongside somatotrophs. At doses that produce near-maximal GH release, cortisol and ACTH rise through a mechanism involving hypothalamic CRH pathway activation rather than direct pituitary corticotroph stimulation alone. Prolactin also rises in a dose-dependent pattern across effective GH-releasing doses.

The Arvat et al. 1997 comparison (PMID 9285939) documented that hexarelin's cortisol and prolactin co-stimulation exceeded that of GHRH, TRH, and hCRH administered separately at reference doses, suggesting a mixed hypothalamic-pituitary mechanism. This non-selective activation of the HPA axis is the main pharmacological reason later protocols moved toward ipamorelin when GH isolation was the research objective, as ipamorelin produces minimal cortisol or prolactin elevation at equivalent GH-releasing doses.

Desensitization with repeated dosing

Sustained GHS-R1a agonism produces receptor internalization, and the GH response to hexarelin attenuates progressively with repeated administration. A study examining whether desensitization occurs over a 16-week protocol of twice-daily subcutaneous hexarelin in healthy elderly subjects (PMID 10990150) found that mean GH AUC fell from 19.1 +/- 2.4 mcg/l/hour at baseline to 10.5 +/- 1.8 mcg/l/hour by week 16, a reduction of roughly 45%. Four weeks after stopping, GH responses returned to near-baseline, confirming the receptor downregulation was reversible.

The rate of attenuation is dose-dependent: higher doses produce faster blunting of the GH response. In single-dose paradigms, the GH pulse remains at its full magnitude. In research settings, this desensitization profile makes hexarelin better suited to intermittent or short-course protocols rather than sustained continuous administration.

For comparison, the CJC-1295 and ipamorelin research overview covers how the DAC modification on CJC-1295 was specifically designed to achieve sustained GH release by extending receptor half-life rather than continuous dosing.

Cardiac effects: cardioprotection via CD36

The cardiac pharmacology of hexarelin was first identified when the peptide protected postischemic cardiac function in GH-deficient rat models, an effect that persisted without pituitary GH. A photoactivatable hexarelin derivative was subsequently used to cross-link the compound to its putative cardiac receptor, identifying CD36 in cardiac tissue and confirming a mechanism distinct from GHS-R1a.

A 2014 review in Acta Physiologica ("The cardiovascular action of hexarelin," PMID 25278975) summarized the dual-receptor model across multiple rodent studies: hexarelin reduced infarct size, preserved cardiac output, limited cardiomyocyte apoptosis, and attenuated pathological fibrosis in ischemia models. CD36 was identified as the predominant mediator in peripheral cardiac tissue where GHS-R1a expression is lower, while GHS-R1a contributed to effects in cardiac regions with higher receptor density.

A 2017 study in Frontiers in Physiology (PMID 28321024, rat ischemia-reperfusion model, n=48) found that hexarelin added to the perfusion system post-ischemia reduced cardiomyocyte apoptosis by modulating the IL-1 signaling pathway, specifically lowering IL-1beta expression in ischemic zones. A 2020 mouse model study (PMID 32403043) further characterized neuroinflammatory pathway modulation as an additional mechanism through which hexarelin preserves cardiac morphology after infarction.

All cardiac findings to date are from rodent models. No controlled human trials have examined hexarelin as a cardioprotective agent, which limits direct translation to human cardiac physiology.

Comparison to ipamorelin and GHRP-6

Hexarelin, ipamorelin, and GHRP-6 all bind GHS-R1a and stimulate GH secretion but differ substantially in receptor selectivity, secondary hormone activation, and peripheral receptor binding.

On a per-microgram basis, hexarelin produces the strongest acute GH pulse of the three. GHRP-6 stimulates appetite through ghrelin-related pathways, an effect hexarelin does not replicate at equivalent doses. Ipamorelin was designed for receptor selectivity: at GH-releasing doses, it produces minimal cortisol, ACTH, or prolactin elevation, which is the main reason it became the preferred GHRP in protocols where isolating GH secretion was the research objective.

Where hexarelin's dual GHS-R1a/CD36 mechanism or its cardiac-specific pharmacology is the research focus, neither ipamorelin nor GHRP-6 provides an equivalent tool. Neither binds CD36 with hexarelin's affinity, and the cardiac receptor findings have not been replicated for those peptides in the same literature.

Hexarelin research: status and limitations

Hexarelin entered human clinical trials in the 1990s but was not approved for any therapeutic indication. The combination of progressive GH desensitization and cortisol/prolactin co-stimulation limited its utility as a long-term therapeutic candidate. Modified GHRH analogues followed a separate regulatory path, with tesamorelin receiving FDA approval for HIV-associated lipodystrophy while hexarelin's development program was discontinued.

The cardiac CD36 receptor findings remain one of the more pharmacologically specific results from the GHRP literature. Identifying a synthetic GH secretagogue with a second, structurally distinct cardiac receptor that operates independently of the pituitary GH axis was unexpected at the time and opened a line of mechanistic investigation into growth hormone secretagogue cardiac pharmacology that continues.

All findings described here come from published scientific research. Hexarelin is not approved for human therapeutic use. Research applications are limited to scientific investigation in appropriate laboratory settings.

Hexarelin research: GH release, cardiac effects, and secretagogue comparison+